Efficacy and safety of de-escalation bone- modifying agents for cancer patients with bone metastases: a systematic review and meta-analysis

References

• HofbauerLCRachnerTDColemanREJakobFEndocrine aspects of bone metastasesLancet Diabetes Endocrinol20142650051224880565
   PubMed Web of Science ®Google Scholar
• Clément-DemangeLClézardinPEmerging therapies in bone metastasisCurr Opin Pharmacol201522798625935860
   PubMed Web of Science ®Google Scholar
• BrownJECookRJMajorPBone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumorsJ Natl Cancer Inst2005971596915632381
   PubMed Web of Science ®Google Scholar
• BrownJEThomsonCSEllisSPGutcherSAPurohitOPColemanREBone resorption predicts for skeletal complications in metastatic bone diseaseBr J Cancer200389112031203714647134
   PubMed Web of Science ®Google Scholar
• Gómez GarcíaSClemonsMAmirERethinking end-points for bone- targeted therapy in advanced cancerEur J Cancer20166310510927299662
   PubMed Web of Science ®Google Scholar
• SaadFLiptonACookRChenYMSmithMColemanRPathologic fractures correlate with reduced survival in patients with malignant bone diseaseCancer200711081860186717763372
   PubMed Web of Science ®Google Scholar
• GreenJRMüllerKJaeggiKAPreclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compoundJ Bone Miner Res1994957457518053405
   PubMed Web of Science ®Google Scholar
• ColemanREBisphosphonates: clinical experienceOncologist20049Suppl 41427
   PubMedGoogle Scholar
• ClemonsMGelmonKAPritchardKIPatersonAHBone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the artCurr Oncol201219525926823144574
   PubMed Web of Science ®Google Scholar
• HolenIColemanREBisphosphonates as treatment of bone metastasesCurr Pharm Des201016111262127120166976
   PubMed Web of Science ®Google Scholar
• HuttonBAddisonCMazzarelloSDe-escalated administration of bone-targeted agents in patients with breast and prostate cancer-A survey of Canadian oncologistsJ Bone Oncol201322778326909274
   PubMed Web of Science ®Google Scholar
• HortobagyiGNTheriaultRLPorterLEfficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study GroupN Engl J Med199633524178517918965890
   PubMed Web of Science ®Google Scholar
• HenryDHCostaLGoldwasserFRandomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myelomaJ Clin Oncol20112991125113221343556
   PubMed Web of Science ®Google Scholar
• CremersSCPapapoulosSEGelderblomHSkeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastasesJ Bone Miner Res20052091543154716059626
   PubMed Web of Science ®Google Scholar
• DoshiSSutjandraLZhengJDenosumab dose selection for patients with bone metastases from solid tumorsClin Cancer Res20121892648265722394983
   PubMed Web of Science ®Google Scholar
• van PoznakCSomerfieldMRBarlowWERole of Bone- Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline UpdateJ Clin Oncol201735353978398629035643
   PubMed Web of Science ®Google Scholar
• BouganimNDranitsarisGAmirEClemonsMOptimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologistsSupport Care Cancer201119111687169621785900
   PubMed Web of Science ®Google Scholar
• AmadoriDAgliettaMAlessiBEfficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open- label, randomised, non-inferiority trialLancet Oncol201314766367023684411
   PubMed Web of Science ®Google Scholar
• HimelsteinALFosterJCKhatcheressianJLEffect of Longer- Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical TrialJAMA20173171485828030702
   PubMed Web of Science ®Google Scholar
• HortobagyiGNvan PoznakCHarkerWGContinued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical TrialJAMA Oncol20173790691228125763
   PubMed Web of Science ®Google Scholar
• AddisonCLPondGRZhaoHEffects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastasesSpringerplus2014357725332877
   PubMedGoogle Scholar
• AmirEFreedmanOCarlssonLRandomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancerAm J Clin Oncol201336543644222781385
   PubMed Web of Science ®Google Scholar
• LiptonAStegerGGFigueroaJRandomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastasesJ Clin Oncol200725284431443717785705
   PubMed Web of Science ®Google Scholar
• FizaziKLiptonAMarietteXRandomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonatesJ Clin Oncol200927101564157119237632
   PubMed Web of Science ®Google Scholar
• LiptonAStegerGGFigueroaJExtended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapyClin Cancer Res200814206690669618927312
   PubMed Web of Science ®Google Scholar
• LiberatiAAltmanDGTetzlaffJThe PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaborationBMJ2009339b270019622552
   PubMed Web of Science ®Google Scholar
• KnoblochKYoonUVogtPMPreferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication biasJ Craniomaxillofac Surg2011392919221145753
   PubMed Web of Science ®Google Scholar
• ShamseerLMoherDClarkeMPreferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanationBMJ2015350g764725555855
   PubMed Web of Science ®Google Scholar
• HigginsJPAltmanDGGøtzschePCThe Cochrane Collaboration’s tool for assessing risk of bias in randomised trialsBMJ2011343d592822008217
   PubMed Web of Science ®Google Scholar
• ChanKKGlennyAMWeldonJCFurnessSWorthingtonHVWakefordHInterventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapyCochrane Database Syst Rev20151212CD010341
   Google Scholar
• SongFSheldonTASuttonAJAbramsKRJonesDRMethods for exploring heterogeneity in meta-analysisEval Health Prof200124212615111523383
   PubMed Web of Science ®Google Scholar
• BerensonJRRosenLSHowellAZoledronic acid reduces skeletal-related events in patients with osteolytic metastasesCancer20019171191120011283917
   PubMed Web of Science ®Google Scholar
• KuchukIBeaumontJLClemonsMAmirEAddisonCLCellaDEffects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkersJ Bone Oncol20132415415726909286
   PubMed Web of Science ®Google Scholar
• BodyJJLiptonAGralowJEffects of denosumab in patients with bone metastases with and without previous bisphosphonate exposureJ Bone Miner Res201025344044619653815
   PubMed Web of Science ®Google Scholar
• ColemanREWrightJHoustonSRandomized trial of marker- directed versus standard schedule zoledronic acid for bone metastases from breast cancerJ Clin Oncol20123015 Suppl511
   Web of Science ®Google Scholar
• AmirEFreedmanOCarlssonLP4-16-08: Pilot Randomized Trial of De-Escalated (q12 Weekly) Versus Standard (q3-4 Weekly) Intravenous Bisphosphonates in Women with Low-Risk Bone Metastases from Breast CancerCancer Res20117124 Suppl P4-16-08P4-16-08-P4-16-08
   Google Scholar
• TempletonAJStalderLAlbiges SauvinLPrevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE)Ann Oncol201425Suppl 4iv540iv541
   Google Scholar
• BodyJFizaziKStegerGGEffects of denosumab on bone turnover: Results from two randomized phase 2 trials in patients with solid tumorsAnn Oncol200819S8viii275viii276
   Google Scholar
• KimmelDBMechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonatesJ Dent Res200786111022103317959891
   PubMed Web of Science ®Google Scholar
• KuchukIMazzarelloSButterfieldKAppletonAAddisonCLClemonsMOral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologistsJ Bone Oncol201321384626909271
   PubMed Web of Science ®Google Scholar
• MariottiABisphosphonates and osteonecrosis of the jawsJ Dent Educ200872891992918676801
   PubMed Web of Science ®Google Scholar
• XieJDienerMSorgRWuEQNamjoshiMCost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastasesClin Breast Cancer201212424725822694824
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN) [homepage on the Internet]Clinical Practice Guidelines in OncologyBreast Cancer Version 22017Accessed September 6, 2018 https://www.nccn.org/professionals/physician_gls/default.aspx
   Google Scholar
• National Comprehensive Cancer Network (NCCN) [homepage on the Internet]Clinical Practice Guidelines in OncologyMultiple Myeloma Version 32017 https://www.nccn.org/professionals/physician_gls/default.aspxAccessed September 6, 2018
   Google Scholar
• National Comprehensive Cancer Network (NCCN) [homepage on the Internet]Clinical Practice Guidelines in OncologyProstatic cancer Version 22017 https://www.nccn.org/professionals/physician_gls/default.aspxAccessed September 6, 2018
   Google Scholar
• MajorPPCookREfficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpointsAm J Clin Oncol2002256 Suppl 1S10S1812562046
   PubMed Web of Science ®Google Scholar
• HussainAAlyADaniel MullinsCQianYArellanoJOnukwughaERisk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosisCancer Med20165113300330927730756
   PubMed Web of Science ®Google Scholar
• ClampADansonSNguyenHColeDClemonsMAssessment of therapeutic response in patients with metastatic bone diseaseLancet Oncol200451060761615465464
   PubMed Web of Science ®Google Scholar
• ColemanRCostaLSaadFConsensus on the utility of bone markers in the malignant bone disease settingCrit Rev Oncol Hematol201180341143221411334
   PubMed Web of Science ®Google Scholar
• KuchukIClemonsMAddisonCTime to put an end to the “one size fits all” approach to bisphosphonate use in patients with metastatic breast cancer?Curr Oncol2012195e303e30423144577
   PubMed Web of Science ®Google Scholar
• LaceyDLTimmsETanHLOsteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activationCell19989321651769568710
   PubMed Web of Science ®Google Scholar
• ZhangZPuFShaoZThe skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trialsJ Bone Oncol20179212429123990
   PubMed Web of Science ®Google Scholar
• ZhangXHamadehISSongSOsteonecrosis of the Jaw in the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS)J Bone Miner Res201631233634026288087
   PubMed Web of Science ®Google Scholar
• ShapiroCLMoriartyJPDusetzinaSCost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance)J Clin Oncol201735353949395529023215
   PubMed Web of Science ®Google Scholar
• BodyJJColemanRClezardinPInternational Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patientsEur J Cancer200743585285817258449
   PubMed Web of Science ®Google Scholar
• ColemanREMetastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treat Rev200127316517611417967
   PubMed Web of Science ®Google Scholar